<DOC>
	<DOCNO>NCT01189903</DOCNO>
	<brief_summary>1 . Primary Endpoints - Biomarker data suggestive regorafenib-mediated inhibition RAS-RAF- MEK-ERK signal transduction pathway , various tyrosine kinase receptor and/or angiogenesis . - Evaluation potential relationship biomarker data clinical activity . - Evaluation novel biomarker technology ( Prometheus COPIA platform ) 2 . Secondary Endpoints - Biomarker data suggestive regorafenib-mediated effect circulate rare cell . - Comparison tumor genetic profile obtain use DNA isolated plasma , tumor biopsy circulate tumor cell . - Patient safety data - Pharmacokinetics regorafenib - Changes tumor metabolic activity measure PET CT scan ( optional )</brief_summary>
	<brief_title>Clinical Evaluation - A Phase IIA Proof Concept Study Regorafenib ( Bayer 73-4506 ) Biopsy-amenable Asian Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Niclosamide</mesh_term>
	<criteria>Histologically cytologically proven metastatic colorectal adenocarcinoma refractory standard therapy amenable surgery curative intent . Tumor characteristic : At least one lesion suitable repeat biopsy ; eg . subcutaneous nodule , skin lesion , rectal tumor , colonic mass easily reach colonoscopy , peritoneal mass least 3cm maximum diameter easily assessable image guide core biopsy . For liver lesion , superficially locate lesion least 3cm maximum dimension rim normal liver tissue , assessable safely image guide core biopsy determine experienced interventional radiologist . Eastern Cooperative Oncology Group ECOG performance status 0 1 ( see Appendix 10.4 ) . Adequate bone marrow function ( absolute neutrophil count =1,500/mm3 ; platelet count =100000/mm3 ; hemoglobin =9g/dl Adequate liver renal function assess follow laboratory requirement conduct within 7 day start study treatment : Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver involvement cancer ) . Amylase lipase &lt; 1.5 x ULN Serum creatinine &lt; 1.5 x ULN . Glomerular filtration rate ( GFR ) = 30 ml/min/1.73 m2 accord MDRD ( Modified diet renal disease ) abbreviate formula Prothrombin time , international normalize ratio ( INR ) partial thromboplastin time le equal 1.2 time ULN . Male female least 21 year age . A female subject eligible enter participate study : Nonchildbearing potential ( ie . physiologically incapable become pregnant ) include woman : Has hysterectomy Has bilateral oophorectomy ( ovariectomy ) Has bilateral tubal ligation Is postmenopausal ( demonstrate total cessation menses great Childbearing potential , negative serum urine pregnancy test screening , agree one following : double barrier contraception abstinence . Predicted life expectancy least 12 week . Resting oxygen saturation great 92 % room air . Written informed consent . Able swallow retain oral medication . Prothrombin time ( PT ) , International Normalized Ratio PT ( PT INR ) , partial thromboplastin time ( PTT ) activate partial thromboplastin time ( aPTT ) within normal limit .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>